# Cheiron

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cheiron

- Industry: Software
- Headquarters: Los Altos, US
- Website: www.cheiron.bio
- Total disclosed funding: $8M
- Latest round: Seed (Jul 22, 2026)
- Investors on record: 1

## About

Founded in 2024 by CEO Minseok Bae, CPO Jason Park and CTO Harshit Gupta, PhnyX Lab Inc. d.b.a. Cheiron operates out of California, US focusing on providing an integrated platform for drug program management in the biopharma industry. In July 2026, the company raised USD 8.00 mn in Seed funding led by Menlo Ventures, marking its first funding round. 

Cheiron offers a comprehensive AI-powered operating system designed specifically for the biopharma industry, enabling seamless integration of drug program management. Its core product connects various aspects of drug development, including protocols, submissions, study results, and regulatory commitments, into a unified platform. This system allows teams to promptly access relevant information when changes occur, ensuring that all stakeholders are informed and can respond effectively to updates. By streamlining workflows and providing a centralized repository for critical documents, Cheiron aims to enhance operational efficiency and reduce time to market for drug approvals. The company primarily serves pharmaceutical companies and research organizations across North America and Europe, providing tools that facilitate the management of complex drug development programs.

Cheiron's revenue model revolves around subscriptions to its AI-driven operating system, catering to B2B transactions with pharmaceutical companies and biotech firms. The company generates income through tiered subscription plans that offer varying levels of access to its suite of tools and functionalities, tailored to the needs of different client sizes and project scopes. Engaging clients typically involves an initial setup fee, followed by recurring subscription payments that cover ongoing access to the platform and support services. Given its focus on drug program management, Cheiron’s offerings include proprietary features that assist clients with compliance, documentation, and regulatory processes. The structured nature of these transactions allows clients to budget effectively while ensuring they benefit from the latest advancements in drug program management technology.

In July 2026, Cheiron raised USD 8.00 mn in Seed funding, which may be utilized to accelerate development of its Life Sciences Knowledge Graph, expand capabilities across clinical, regulatory, and strategic workflows, and grow engineering, product, and life sciences teams.

## Funding rounds

- Seed, Jul 22, 2026, $8M — Menlo Ventures

## Investors

- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Seed